Agios Pharmaceuticals, Inc. (AGIO): who owns it and who trades it
As of Nov 16, 2026, AGIO insiders reported 29 open-market sales worth $4.3M and no purchases in the last 12 months, with 96% of the sale value made under pre-set 10b5-1 plans. The largest seller was Brian Goff (CEO), with $1.7M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Agios Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors and Congress mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AGIO
237 funds and institutions reported AGIO shares worth $2.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 10.9%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 6.46M | 10.86% | $240M | +12% |
| Farallon Capital Management, L.l.c. | 5.92M | 9.95% | $220M | +4% |
| State Street Corp | 3.53M | 5.94% | $131M | +5% |
| Lynx1 Capital Management LP | 3.41M | 5.73% | $127M | +31% |
| D. E. Shaw & Co., Inc. | 3.11M | 5.22% | $115M | +16% |
| Vanguard Portfolio Management LLC | 2.90M | 4.87% | $108M | +11% |
| Vanguard Capital Management LLC | 2.68M | 4.51% | $99.5M | +2% |
| California State Teachers Retirement System | 2.48M | 4.17% | $66.8M | +3515% |
| Armistice Capital, LLC | 2.40M | 4.04% | $89.1M | -12% |
| Erste Asset Management GmbH | 2.15M | 3.62% | $82M | -20% |
| Nomura Asset Management International Inc. | 2.11M | 3.55% | $78.3M | +41% |
| Geode Capital Management, LLC | 1.57M | 2.65% | $58.4M | +7% |
| Susquehanna International Group, LLP | 1.38M | 2.31% | $51M | +2% |
| ADAR1 Capital Management, LLC | 1.29M | 2.17% | $47.8M | +816% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.28M | 2.15% | $47.5M | -19% |
| Dimensional Fund Advisors LP | 1.25M | 2.10% | $46.3M | +8% |
| GW&K Investment Management, LLC | 1.21M | 2.03% | $44.8M | -1% |
| Goldman Sachs Group Inc | 1.15M | 1.94% | $42.7M | +43% |
| UBS Group AG | 985,831 | 1.66% | $36.6M | +644% |
| Morgan Stanley | 963,256 | 1.62% | $35.7M | -0% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AGIO insiders reported $0 of open-market purchases and $4.3M of sales. 96% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 26, 2026 | Sarah Gheuens | Chief Medical Officer | Sale plan | 7,866 | $37.69 | $296K | Form 4 |
| Oct 22, 2026 | Sarah Gheuens | Chief Medical Officer | Sale plan | 500 | $37.52 | $18.8K | Form 4 |
| Oct 21, 2026 | Sarah Gheuens | Chief Medical Officer | Sale plan | 1,489 | $37.53 | $55.9K | Form 4 |
| Aug 4, 2026 | Sarah Gheuens | Chief Medical Officer | Sale plan | 30,000 | $30.48 | $914K | Form 4 |
| Jul 1, 2026 | Sarah Gheuens | Chief Medical Officer | Sale plan | 4,007 | $37.56 | $151K | Form 4 |
| Apr 2, 2026 | James William Burns | Chief Legal Officer | Sale plan | 3,280 | $34.71 | $114K | Form 4 |
| Apr 2, 2026 | Sarah Gheuens | Chief Medical Officer | Sale plan | 2,940 | $34.71 | $102K | Form 4 |
| Apr 2, 2026 | Cecilia Jones | CFO | Sale plan | 3,141 | $34.71 | $109K | Form 4 |
| Apr 2, 2026 | Tsveta Milanova | Chief Commercial Officer | Sale plan | 3,262 | $34.71 | $113K | Form 4 |
| Apr 2, 2026 | Krishnan Viswanadhan | Chief Corp Dev & Strateg | Sale plan | 2,959 | $34.71 | $103K | Form 4 |
| Apr 2, 2026 | Brian Goff | CEO | Sale plan | 12,472 | $34.71 | $433K | Form 4 |
| Apr 2, 2026 | Brian Goff | CEO | Sale plan | 6,596 | $34.71 | $229K | Form 4 |
| Mar 5, 2026 | Krishnan Viswanadhan | Chief Corp Dev & Strateg | Sale plan | 2,959 | $27.80 | $82.3K | Form 4 |
| Mar 3, 2026 | Theodore James Washburn Jr. | Principal Accounting Off | Sale | 5,272 | $28.88 | $152K | Form 4 |
| Mar 2, 2026 | Brian Goff | CEO | Sale plan | 5,918 | $28.96 | $171K | Form 4 |
| Mar 2, 2026 | Brian Goff | CEO | Sale plan | 3,870 | $28.96 | $112K | Form 4 |
| Mar 2, 2026 | Brian Goff | CEO | Sale plan | 8,267 | $28.96 | $239K | Form 4 |
| Mar 2, 2026 | James William Burns | Chief Legal Officer | Sale plan | 1,187 | $28.96 | $34.4K | Form 4 |
| Mar 2, 2026 | James William Burns | Chief Legal Officer | Sale plan | 1,681 | $28.96 | $48.7K | Form 4 |
| Mar 2, 2026 | James William Burns | Chief Legal Officer | Sale plan | 1,163 | $28.96 | $33.7K | Form 4 |
| Mar 2, 2026 | Cecilia Jones | CFO | Sale plan | 594 | $28.96 | $17.2K | Form 4 |
| Mar 2, 2026 | Cecilia Jones | CFO | Sale plan | 1,573 | $28.96 | $45.6K | Form 4 |
| Mar 2, 2026 | Theodore James Washburn Jr. | Principal Accounting Off | Sale plan | 698 | $28.96 | $20.2K | Form 4 |
| Mar 2, 2026 | Theodore James Washburn Jr. | Principal Accounting Off | Sale plan | 727 | $28.96 | $21.1K | Form 4 |
| Mar 2, 2026 | Theodore James Washburn Jr. | Principal Accounting Off | Sale plan | 798 | $28.96 | $23.1K | Form 4 |
| Jan 5, 2026 | Tsveta Milanova | Chief Commercial Officer | Sale plan | 2,872 | $27.02 | $77.6K | Form 4 |
| Dec 30, 2025 | James William Burns | Chief Legal Officer | Sale plan | 2,932 | $27.09 | $79.4K | Form 4 |
| Dec 30, 2025 | Brian Goff | CEO | Sale plan | 12,473 | $27.09 | $338K | Form 4 |
| Dec 30, 2025 | Brian Goff | CEO | Sale plan | 6,230 | $27.09 | $169K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Brian Goff | Chief Executive Officer, Director | – | $1.7M | Apr 2, 2026 |
| Sarah Gheuens | Chief Medical Officer | – | $1.5M | Oct 26, 2026 |
| James William Burns | Chief Legal Officer | – | $310K | Apr 2, 2026 |
| Theodore James Washburn Jr. | Principal Accounting Officer | – | $217K | Mar 3, 2026 |
| Tsveta Milanova | Chief Commercial Officer | – | $191K | Apr 2, 2026 |
| Krishnan Viswanadhan | Chief Corp Dev & Strategy | – | $185K | Apr 2, 2026 |
| Cecilia Jones | Chief Financial Officer | – | $172K | Apr 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AGIO short interest
High short interest. 10.9% of AGIO shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went down 12%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.52M AGIO shares were sold short, 10.9% of the shares outstanding, down 5.4% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 5.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.52M | 10.91% | -5% | 1.26M | 5.2 |
| Oct 15, 2026 | 6.89M | 11.55% | -2% | 1.23M | 5.6 |
| Sep 30, 2026 | 7.02M | 11.75% | -7% | 1.09M | 6.4 |
| Sep 15, 2026 | 7.56M | 12.66% | +0% | 798,861 | 9.5 |
| Aug 31, 2026 | 7.54M | 12.62% | -1% | 893,037 | 8.4 |
| Aug 14, 2026 | 7.63M | 12.78% | +12% | 1.09M | 7.0 |
| Jul 31, 2026 | 6.84M | 11.46% | +3% | 1.33M | 5.1 |
| Jul 15, 2026 | 6.63M | 11.15% | -2% | 1.03M | 6.4 |
| Jun 30, 2026 | 6.76M | 11.36% | -2% | 1.33M | 5.1 |
| Jun 15, 2026 | 6.90M | 11.60% | -0% | 1.04M | 6.6 |
| May 29, 2026 | 6.93M | 11.65% | -7% | 848,565 | 8.2 |
| May 15, 2026 | 7.45M | 12.53% | +7% | 859,103 | 8.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded AGIO
Since Nov 17, 2024, 1 member of Congress reported 5 purchases and 0 sales of AGIO. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Aug 20, 2026, reported Sep 10, 2026.
Purchases 5Sales 0
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Sep 10, 2026 | Report |
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Apr 7, 2026 | Report |
| Dec 11, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jan 12, 2026 | Report |
| Apr 17, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | May 6, 2025 | Report |
| Jan 29, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Feb 11, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Agios Pharmaceuticals company events
Agios Pharmaceuticals filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jun 18, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of Agios Pharmaceuticals, Inc. held on June 18, 2026, the Company’s stockholders approved an amendment to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan. Filing
- Apr 29, 2026ResultsReleased financial results. Filing
- Feb 12, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Agios Pharmaceuticals financials
Famous investors that hold AGIO
5 of the 50 well-known investors we track reported holding AGIO in their latest 13F filing. The largest position is Ken Griffin's, worth $25.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 778,581 | $25.9M | 0.0% | +6% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 505,600 | $16.8M | 0.0% | New |
| Larry Robbins · Glenview Capital Management | Q3 2026 | 459,792 | $15.3M | 0.3% | New |
| Israel Englander · Millennium Management | Q3 2026 | 274,439 | $9.1M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 52,832 | $1.8M | 0.0% | -20% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named AGIO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Lynx1 Capital Management LP | 13G/A | 0.8% |
| Nov 16, 2026 | D. E. Shaw & Co., L.P. | 13G/A | 6.5% |
| Nov 16, 2026 | D. E. Shaw & Co., L.P. | 13G/A | 6.5% |
| Nov 16, 2026 | Lynx1 Capital Management LP | 13G/A | 0.8% |
| Nov 13, 2026 | Morgan Stanley | 13G | 5.7% |
| Nov 13, 2026 | Morgan Stanley | 13G | 5.7% |
Questions about Agios Pharmaceuticals, Inc. (AGIO) stock
Who owns the most AGIO stock?
The largest reported owner of Agios Pharmaceuticals, Inc. (AGIO) is BlackRock, Inc., with 10.9% of the company. In total, 237 funds and institutions reported holding AGIO at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are AGIO insiders buying or selling?
In the last 12 months, AGIO insiders reported no open-market purchases and 29 sales worth $4.3M. The latest trade was on Oct 26, 2026. See every trade.
What is the short interest in AGIO?
As of Oct 30, 2026, 6.52M AGIO shares were sold short, 10.9% of the shares outstanding, down 5.4% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 5.2 trading days (days to cover). See the history.
Have members of Congress traded AGIO?
Yes. 1 member of Congress reported 5 purchases and 0 sales of AGIO since Nov 17, 2024. The latest was reported on Sep 10, 2026. See the trades.
Which famous investors hold AGIO?
5 of the 50 well-known investors we track reported AGIO in their latest 13F filing, including Ken Griffin, Jim Simons, Larry Robbins. The largest position is worth $25.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.